CLLS News
Archived Headlines
- CAR T goes into overdrive: Cellectis increases proposed IPO deal size by 50% 03/24/15
- Week ahead: Up to 9 IPOs during the week of March 23 led by a billion-dollar biotech 03/22/15
- Cancer biotech Cellectis sets terms for $129 million IPO 03/18/15
- Gene-edit the cancer out: Cellectis files for a $115 million US IPO 02/20/15
Cream of the gene-edited crop: Calyxt sets terms for $100 million IPO
Calyxt, a developer of gene-edited crop traits spun out of Cellectis, announced terms for its IPO on Monday. The New Brighton, MN-based company plans to raise $100 million by offering 6.06 million shares at a price range of $15 to $18. Parent Cellectis may...read more
Survival of the fittest biotechs: Galapagos sets terms for $160 million US IPO
Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, announced terms for its IPO on Tuesday. The Mechelen, Belgium-based company plans to raise $160 million by offering 3.78 million ADSs. Its shares are currently listed on...read more
US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat
Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly jump...read more
Cellectis prices upsized IPO at $41.50, selling 750k additional ADSs over upwardly revised deal size
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T cells, raised $229 million in an upsized IPO by offering 5.5 million ADSs (all primary) at $41.50. The Paris, France-based company had planned to offer 4.8 million ADSs, upwardly...read more